12 March 2002
Resistance of Klebsiella pneumoniae strains producing and not producing ESBL(extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.
Maria Szymankiewicz, Marcin Wróblewski, Grazyna Janicka, Alicja Sekowska, Małgorzata Wojda, Czesław KłyszejkoMed Sci Monit 2002; 8(3): BR100-104 :: ID: 420891
Abstract
BACKGROUND: Bacteria of the Klebsiella genus may cause numerous infectionsin human, which are often treated with beta-lactam antibiotics. The fundamental mechanism of Klebsiellaresistance to penicillins or cephalosporins involves the production of enzymes--extended-spectrum beta-lactamases(ESBLs). Because of resistance of many Klebsiella spp. strains to beta-lactams, alternative antibiotictherapy can make use of aminoglycosides and quinolones. MATERIAL/METHODS: The study analyzed the prevalenceof ESBL -type enzymes among 256 Klebsiella pneumoniae strains isolated from various clinical materialscollected from patients hospitalized between 1997 and 2000. ESBLs were detected by double-disk synergytest (DDST). The prevalence of strains resistant to selected aminoglycosides (gentamicin, amikacin, netilmicin)and quinolones (ciprofloxacin, norfloxacin, nalidixic acid) in the particular years was analyzed. Drugsensitivity was determined by disk-diffusion method according to the recommendations of the NationalReference Center for Microbial Drug Sensitivity. RESULTS: During the analyzed time interval, a significantincrease of the number of K. pneumoniae ESBL(+) strains was noted: in 1997 - 16.5% (14/85) and in 2000- 40.4% (22/54) (p<0.001).Among the ESBL(+) strains, an increase of the number of strains resistant to the tested antibiotics, except for nalidixic acid, was demonstrated
Conclusion: A statistically significant increase of multidrug-resistant K. pneumoniae strains, including strains producing ESBLs, was demonstrated in the analyzed material
Keywords: amikacin, Anti-Bacterial Agents, Anti-Infective Agents, Ciprofloxacin, Drug Resistance, Microbial, Gentamicins, Klebsiella pneumoniae, Microbial Sensitivity Tests, Nalidixic Acid, Netilmicin, Norfloxacin, Prevalence, Time Factors, beta-Lactamases
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952